Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.33 |
| ▸ | POLR1A | O95602 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SMO | Q99835 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2376964 | 0.90 | JAK2 (0.37) | JAK2JAK1JAK3DGAT1HTR2C | |
| SCHEMBL2379002 | 0.86 | HCRTR1 (0.34) | JAK2JAK1JAK3DGAT1ALDH1A1 | |
| SCHEMBL2377365 | 0.85 | JAK2 (0.39) | JAK2JAK1JAK3DGAT1 | |
| SCHEMBL2379368 | 0.85 | HCRTR1 (0.34) | JAK2JAK1JAK3DGAT1ALDH1A1 | |
| SCHEMBL2378283 | 0.85 | JAK2 (0.35) | JAK2JAK1JAK3DGAT1 | |
| SCHEMBL2378288 | 0.84 | PRMT5 (0.40) | ALDH1A1LMNA | |
| SCHEMBL2378212 | 0.84 | JAK2 (0.45) | JAK2JAK1JAK3DGAT1MCHR1 | |
| SCHEMBL2378129 | 0.84 | JAK3 (0.35) | JAK2JAK1JAK3DGAT1 | |
| SCHEMBL2378512 | 0.83 | DPP4 (0.33) | JAK2JAK1JAK3DGAT1KDM4E | |
| SCHEMBL2378996 | 0.82 | JAK2 (0.37) | JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | JAK2 5/4885JAK1 1/4885JAK3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.